NON SMALL CELL LUNG CANCER

This study aimed to test if a drug called capmatinib, given before and after surgery, could help people with certain types of non-small cell lung cancer that have specific genetic changes. The goal was to see if the drug could shrink tumors before surgery and prevent the cancer f…

This early-stage study tested a new cancer drug called PF-07820435, both alone and combined with an existing immunotherapy drug (sasanlimab), in people with advanced solid tumors. The main goals were to find safe doses and look for early signs that the treatment might help shrink…

This was an early-stage study to test the safety and find the right dose of a new cancer drug called PF-07265028. It was given alone and in combination with another immunotherapy drug, sasanlimab, to a small group of people with advanced solid tumors that had stopped responding t…

This was an early safety study of a new oral drug called TAS2940 for people with advanced solid tumors that have specific genetic changes (EGFR or HER2). The main goals were to find a safe dose and see how the body processes the drug. The trial was terminated and enrolled 29 part…

This study tested whether adding an experimental drug called SAR444245 to other cancer treatments could help control advanced lung cancer or mesothelioma. It involved 106 adults whose cancer had progressed despite prior treatments. The trial was terminated early, and its main goa…

This study tested a new approach for treating advanced non-small cell lung cancer that had spread. The goal was to see if a simple blood test could identify which patients needed to add a short course of chemotherapy to their immunotherapy drugs. The trial was stopped early after…

This small, early-stage study tested a new approach for people with stage III non-small cell lung cancer that could be removed with surgery. The goal was to see if it was safe and practical to give patients a combination of immunotherapy drugs and radiation therapy *before* their…

This early-phase study tested a new treatment called BT-001, which is injected directly into tumors. It was given alone and combined with an existing immunotherapy drug (pembrolizumab) to people with advanced cancers that had spread. The main goals were to find a safe dose and se…

This study tested whether adding an experimental drug called SOT101 to an existing immunotherapy (pembrolizumab) could help control advanced cancers that had stopped responding to other treatments. It involved 166 adults with specific advanced solid tumors, including lung, colore…

This early-stage study aimed to see if adding high-dose vitamin C (ascorbate) to an immunotherapy drug (durvalumab) before surgery could help the body's immune system fight early-stage lung cancer. It compared three approaches: the drug alone, the drug plus vitamin C, or just sur…

This study tested whether adding an immunotherapy drug (pembrolizumab) to a precise form of radiation (SBRT) was better at controlling early-stage lung cancer than radiation alone. It involved 448 adults with early-stage lung cancer who could not have or chose not to have surgery…

This study aimed to find out if patients with advanced non-small cell lung cancer who responded well to immunotherapy could safely stop treatment earlier than usual. Researchers wanted to see if stopping after 6-12 months of response worked as well as continuing treatment longer.…

This study tested a combination of two drugs, tarloxotinib and sotorasib, for people with a specific type of advanced lung cancer (KRAS G12C mutation). It aimed to see if using both drugs together could control the cancer better than sotorasib alone, especially for patients whose…

This early-stage clinical trial tested a new drug called DCC-3084, both alone and combined with other cancer therapies, for people with advanced solid tumors driven by specific genetic mutations. The study aimed to find a safe dose and see if the treatment could shrink tumors in …

This study tested whether combining two immunotherapy drugs could help control several types of advanced cancer. It involved 77 people with cancers like skin cancer, lung cancer, and breast cancer. The trial was terminated early because the drug supply was discontinued, so resear…

This was an early safety study testing a new oral drug called MRTX0902, both alone and combined with another cancer drug (adagrasib), in people with advanced solid tumors that have specific genetic mutations in the KRAS pathway. The main goals were to find safe doses and see how …

This early-stage study tested a personalized cancer treatment that modifies a patient's own immune cells to recognize and attack their specific tumor mutations. The trial enrolled 8 adults with advanced solid tumors (including ovarian, lung, pancreatic, and colorectal cancers) wh…

This was an early-stage study testing a new drug called BDC-3042, both by itself and combined with an existing immunotherapy (cemiplimab), in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find safe doses and see if the tre…

This early-phase study tested a new drug called PRO1107 in patients with advanced solid tumors that had stopped responding to other treatments. The main goals were to find a safe dose and see if the drug could shrink tumors in cancers like ovarian, lung, breast, and others. The s…

This early-stage study tested a new immunotherapy called IMU-201 (PD1-Vaxx) for adults with advanced non-small cell lung cancer. The main goals were to find a safe dose and see if the treatment could help the immune system fight the cancer. The study was small and ended early, so…

This was an early-stage study to test the safety and find the right dose of a new cancer drug called PF-07826390. It was given alone or combined with another immunotherapy drug to people with advanced solid tumors that had spread or stopped responding to treatment. The main goal …

This early-stage study tested the safety of combining an existing immunotherapy drug (atezolizumab) with a new gene therapy (ADV/IL-12) for patients with advanced non-small cell lung cancer. The trial was for people whose cancer had continued to grow despite receiving standard fi…

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer that had stopped responding to hormone therapy, as well as other solid tumors. The trial aimed to see if the drug could slow cancer growth and shrink tumors. The study …

This was an early safety study of a new oral drug called MGY825 for adults with advanced non-small cell lung cancer that had spread or could not be removed by surgery. The main goals were to find a safe dose and see how the body processes the drug. The study also looked for early…

This early-stage study tested a new drug called OC-001, both by itself and combined with an existing immunotherapy drug, in people with various advanced cancers that had stopped responding to standard treatments. The main goal was to check the safety of the drug and see how the b…

This study tested whether adding a new oral drug called HBI-8000 to an existing immunotherapy (pembrolizumab) could help control advanced non-small cell lung cancer. It was designed for adults with a specific biomarker (PD-L1 ≥1%) who had limited prior treatment. The trial was te…

This study tested an experimental drug called telisotuzumab vedotin for adults with advanced non-small cell lung cancer that has a specific genetic feature called MET amplification. The goal was to see if the drug could shrink tumors and control the cancer. The trial was terminat…

This large, late-stage trial tested whether adding an anti-inflammatory drug called canakinumab to standard first-line treatment (chemotherapy plus an immunotherapy drug) could better control advanced non-small cell lung cancer. It involved 673 patients who had not received prior…

This study tested an experimental drug called DAY101 (tovorafenib) in people aged 12 and older with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the drug could shrink or control tumors that have specific genetic changes. The trial …

This study tested whether a combination of two immunotherapy drugs, tiragolumab and atezolizumab, could help control non-small cell lung cancer that had spread to the brain. It was for patients whose brain tumors were not yet causing symptoms and had not been treated. The main go…

This study tested a new type of targeted cancer drug called MYTX-011 in people with advanced non-small cell lung cancer (NSCLC) that had progressed after standard treatments. The main goals were to find a safe dose and see if the drug could shrink tumors, especially in patients w…

This small, early-stage study aimed to find the safest and most effective way to combine two treatments for advanced lung cancer that has spread: a type of precise, high-dose radiation and an immunotherapy drug. Researchers tested whether giving the immunotherapy before or after …

This study aimed to find biological markers in the blood or tumor that could predict how well patients with advanced non-small cell lung cancer respond to a combination of two immunotherapy drugs (ipilimumab and nivolumab). It was a small, early-phase trial that enrolled only 5 p…